SIRT7 and liver cancer: We have previously identified that elevated SIRT7 expression is associated with chemoresistance in human liver cancer, and pan-SIRT inhibitor enhances chemosensitivity to doxorubicin, which suggested SIRT7 may serve as a therapeutic target of liver cancer (Zhao et al., 2019).